【レポートの概要（一部）】
1. Report Overview
1.1 Global Ophthalmic Drugs: Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction To Ophthalmic Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Ophthalmic Treatments – An Industry Overview
2.2 The Human Eyes – Structurally Delicate And Functionally Intricate Organs
2.3 The Global Burden Of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: A Major Cause Of Vision Loss
2.5.1 A Classification Of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors For Glaucoma
2.5.3 Diagnosis Of Glaucoma
2.5.4 Drug Treatment Of Glaucoma
2.5.5 Laser Treatment And Surgery For Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors For AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis Of Diabetic Retinopathy
2.7.2 Treatment Of Diabetic Retinopathy
2.8 Ocular Allergy And Allergic Conjunctivitis
2.8.1 Diagnosis Of Ocular Allergy
2.8.2 Treatment Of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment Of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment Of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Ophthalmic Drugs: Market Definition In This Report
3. The Global Ophthalmic Drugs Market, 2015-2025
3.1 The Global Ophthalmic Drugs Market: Market Overview
3.2 Categorisation Of The Global Ophthalmic Drugs Market
3.3 The Global Ophthalmic Drugs Market In 2014
3.4 The Global Ophthalmic Drugs Market: Market Forecast 2015-2025
3.5 Ophthalmic Drugs: Changing Market Shares By Sector 2015-2025
4. The Retinal Disorder Drugs Market: Market Analysis And Forecast 2015-2025
4.1 Leading Products In The Retinal Disorder Drugs Market, 2014
4.2 Retinal Disorders: Market Trends And Developments, 2015
4.2.1 The Rise And Rise Of Lucentis
4.2.2 The Debate Around Off-Label Avastin Use And The Role Of Novartis And Roche
4.2.3 How Likely Is Avastin’s Expansion Into Age-Related Macular Degeneration?
4.2.4 Jetrea: Underwhelming Sales And ThromboGenics’ Efforts To Reverse It
4.2.5 Drug/Device Combination Products Entering The Market
4.2.6 Does Regenerative Medicine Have A Successful Future In Ophthalmics?
4.3 Retinal Disorder Drugs: Market Forecast 2015-2025
4.3.1 Retinal Disorder Drugs: Changing Market Shares By Leading Drugs 2015-2025
4.4 Leading Drugs For The Treatment Of Retinal Disorders
4.5 Lucentis (ranibizumab) – Roche/ Novartis
4.5.1 Lucentis: Sales Forecast 2015-2025
4.5.2 Less Frequent Dosing Approved In US For Lucentis
4.5.3 New Indications For Lucentis
4.5.4 Possible Combination Therapy Involving Lucentis
4.6 Eylea (aflibercept) – Regeneron/ Bayer/ Santen
4.6.1 Recent Approvals For Eylea
4.6.2 Eylea: Sales Forecast 2015-2025
4.6.3 Possible Combination Therapies Involving Eylea
4.7 Avastin (bevacizumab) – Roche
4.7.1 Avastin: Sales Forecast 2015-2025
4.7.2 Compounding Pharmacies And Safety Risks
4.8 Visudyne (verteporfin) – Valeant/ Novartis
4.8.1 Visudyne: Sales Forecast 2015-2025
4.9 Jetrea (ocriplasmin) – ThromboGenics/ Novartis
4.9.1 Jetrea: Recent Sales Performance
4.9.2 Clinical Study Plans For Jetrea
4.9.3 Jetrea: Sales Forecast 2015-2025
4.9.4 Possible Acquisition Move On ThromboGenics
4.9.5 R&D Agreements With Eleven Biotherapeutics and Bicycle Therapeutics
4.10 Other Retinal Disorder Drugs
4.10.1 Iluvien (fluocinolone implant) – Alimera Sciences
4.10.2 Ozurdex (dexamethasone implant) – Allergan
4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2015-2025
5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis And Forecast 2015-2025
5.1 Leading Products In The Allergic, Inflammatory And Infective Drugs Market, 2014
5.1.1 Allergic, Inflammatory And Infective Drugs: Market Trends And Developments, 2015
5.1.2 The Growth Prospects For Allergic, Inflammatory And Infective Drugs
5.1.3 Topical NSAIDs Launched: Prolensa and Ilevro
5.2 Allergic, Inflammatory And Infective Drugs: Market Forecast 2015-2025
5.2.1 Allergic, Inflammatory And Infective Drugs: Changing Market Shares By Leading Drugs 2015-2025
5.3 Leading Drugs For The Treatment Of Allergic, Inflammatory And Infective Ophthalmic Conditions
5.4 Patanol And Pataday (olopatadine) – Alcon (Novartis)
5.4.1 Pataday: Sales Forecast 2015-2025
5.4.2 Impending Generic Competition For Patanol And Pataday
5.4.3 Approval Of Pazeo Solution
5.4.4 Patanol: Sales Forecast 2015-2025
5.5 Vigamox (moxifloxacin) – Alcon (Novartis)
5.5.1 Intensifying Competition And Generics Drug Challenge To Vigamox
5.5.2 Moxeza: A Next-Generation Form of Vigamox
5.5.3 Vigamox: Sales Forecast 2015-2025
5.6 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis)
5.6.1 The Development And Commercialisation Of TobraDex ST
5.6.2 TobraDex: Sales Forecast 2015-2025
5.7 Bromday (bromfenac) – Valeant
5.7.1 Prolensa: A New Formulation Of Bromfenac
5.7.2 Competition From Ilevro/Nevanac
5.7.3 Bromday: Sales Forecast 2015-2025
5.8 Cravit (levofloxacin) – Santen
5.8.1 Cravit: Sales Forecast 2015-2025
5.9 Acular (ketorolac) – Allergan (Actavis)
5.9.1 Acular: Sales Forecast 2015-2025
5.10 AzaSite (azithromycin) – Akorn
5.10.1 AzaSite: Sales Forecast 2015-2025
5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2015-2025
6. Glaucoma Drugs Market: Market Analysis And Forecast 2015-2025
6.1 Glaucoma Drugs: Market Overview
6.1.1 Leading Products In The Glaucoma Drugs Market, 2014
6.2 Glaucoma Drugs: Market Trends And Developments, 2015
6.2.1 Patent Expiration: A Major Restraint For Glaucoma Drugs
6.2.2 Preservative-Free Formulation Trends
6.2.3 Innovation In Treatments For Glaucoma
6.2.4 Simbrinza: First Beta-Blocker-Free Combination
6.3 Glaucoma Drugs: Market Forecast 2015-2025
6.3.1 Glaucoma Drugs: Changing Market Shares By Leading Drugs 2015-2025
6.4 Leading Drugs For The Treatment Of Glaucoma
6.5 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis)
6.5.1 Lumigan And Ganfort: Sales Forecast 2015-2025
6.6 Xalatan And Xalacom (latanoprost) – Pfizer
6.6.1 Xalatan/Xalacom: Sales Forecast 2015-2025
6.7 Travatan/Travatan Z And DuoTrav (travoprost) – Novartis
6.7.1 Travatan/Travatan Z And DuoTrav: Sales Forecast 2015-2025
6.8 Alphagan/Alphagan P And Combigan (brimonidine) – Allergan
6.8.1 Alphagan/Alphagan P And Combigan: Sales Forecast 2015-2025
6.9 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen
6.9.1 Divestment Agreement With Santen And Akorn
6.9.2 Trusopt: Sales Forecast 2015-2025
6.9.3 Cosopt And Cosopt PF: Sales Forecast 2015-2025
6.10 Azopt (brinzolamide) – Novartis
6.10.1 Azopt: Sales Forecast 2015-2025
6.11 Tapros (tafluprost) – Santen
6.11.1 Tapros: Sales Forecast 2015-2025
6.12 Zioptan (tafluprost) – Akorn
6.12.1 Zioptan: Sales Forecast 2015-2025
6.13 Other Glaucoma Drugs: Sales Forecast 2015-2025
7. Dry Eye Drugs Market: Market Analysis And Forecast 2015-2025
7.1 Dry Eye Drugs: Market Overview
7.1.1 Leading Products In The Dry Eye Drugs Market, 2014
7.2 Dry Eye Drugs: Market Trends And Developments, 2015
7.2.1 Restasis: Patent Elongations And Generic Challenges Creating Uncertainty
7.2.2 Intensifying Research Focused On Dry Eye
7.2.3 Improving Diagnostic Tools
7.3 Dry Eye Drugs: Market Forecast 2015-2025
7.3.1 Dry Eye Drugs: Changing Market Shares By Leading Drugs 2015-2025
7.4 Leading Drugs For The Treatment Of Dry Eye
7.5 Restasis (ciclosporin) – Allergan (Actavis)
7.5.1 Restasis Patent Elongation
7.5.2 Restasis: Sales Forecast 2015-2025
7.6 Refresh Brand Products – Allergan (Actavis)
7.6.1 Refresh Brand Products: Sales Forecast 2015-2025
7.7 Hyalein (hyaluronic acid) – Santen
7.7.1 Hyalein: Sales Forecast 2015-2025
7.8 Diquas (diaquafosol) – Santen
7.8.1 Diquas: Sales Forecast 2015-2025
7.9 Other Dry Eye Drugs: Sales Forecast 2015-2025
7.10 Other Ophthalmic Drugs
7.10.1 Hetlioz (tasimelteon) – Vanda Pharmaceuticals
7.10.1.1 Hetlioz: Sales Forecast 2015-2025
8. Leading National Markets For Ophthalmic Drugs, 2015-2025
8.1 The Ophthalmic Drugs Market By Region
8.1.1 The Global Distribution Of Ophthalmic Drugs In 2014
8.2 Leading National Markets: Forecast 2015-2025
8.2.1 Changing Market Shares By Region, 2015-2025
8.3 Regional Ophthalmic Drugs Markets: Analysis And Forecasts, 2015-2025
8.4 United States: The Largest Ophthalmic Drugs Market
8.4.1 How Will The Rise Of A Biosimilars Market Impact On US Ophthalmic Drugs?
8.4.2 US Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5 EU5
8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
8.5.2 Germany
8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.3 France
8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.4 UK
8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.5 Italy
8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.6 Spain
8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2015-2025
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Ophthalmic Drugs Market Forecast 2015-2025
8.7 China
8.7.1 Expansion Of Healthcare Coverage And Reimbursement In China
8.7.2 Price Controls And The Anhui Model
8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2015-2025
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs
8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.9 Russia
8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.10 India
8.10.1 The Impact Of The Drug Prices Control Order On Indian Pharma
8.10.2 India’s Expansion Of Healthcare Provision
8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.11 Mexico
8.11.1 Mexican Healthcare Reform: Introducing Seguro Popular
8.11.2 Are Multinationals Waking Up To Mexico’s Market Potential?
8.11.3 Mexican Ophthalmic Drugs Market: Market Forecast 2015-2025
8.12 Rest of the World
8.12.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2015-2025
9. Leading Companies In The Ophthalmic Drugs Market, 2015-2025
9.1 Ophthalmic Drugs – A Changing Market Landscape
9.1.1 Leading Companies In The Ophthalmic Drugs Market, 2015
9.1.2 Ophthalmic Drugs Market: Leading Companies Forecast 2015-2025
9.1.3 Ophthalmic Drugs: Changing Market Shares By Leading Companies 2015-2025
9.2 Novartis (Alcon)
9.2.1 Novartis: Ophthalmic Drugs Portfolio, 2015
9.2.2 Novartis: Sales Forecast 2015-2025
9.2.3 Novartis: Ophthalmic Drugs Development Pipeline, 2015
9.2.4 Novartis: Recent Developments
9.2.4.1 Novartis Restructures Following Strategic Review
9.2.4.2 Novartis Licenses Ophthotech’s Fovista
9.3 Allergan (Actavis)
9.3.1 Allergan: Ophthalmic Drugs Portfolio
9.3.2 Allergan: Recent Developments
9.3.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.3.2.2 How Real Is The Threat Of Generic Restasis?
9.3.2.3 Valeant’s Attempted Takeover Squashed By Actavis Bid
9.3.3 Allergan: Sales Forecast 2015-2025
9.3.4 Allergan: Ophthalmic Drugs Development Pipeline, 2015
9.4 Roche
9.4.1 Roche: Ophthalmic Drugs Portfolio, 2015
9.4.1.1 Lucentis: US Sales Forecast 2015-2025
9.4.2 Roche: Sales Forecast 2015-2025
9.4.3 Roche: Ophthalmic Drugs Development Pipeline, 2015
9.5 Santen
9.5.1 Santen: Ophthalmic Drugs Portfolio, 2015
9.5.2 Santen: Recent Developments
9.5.2.1 Santen Acquires Novagali Pharma
9.5.2.2 Santen Acquires Merck’s Ophthalmic Drugs Portfolio
9.5.3 Santen: Sales Forecast 2015-2025
9.5.4 Santen: Ophthalmic Drugs Development Pipeline, 2015
9.6 Regeneron
9.6.1 Regeneron: Ophthalmic Drugs Portfolio, 2015
9.6.2 Regeneron: Recent Developments
9.6.2.1 Expanding Indications For Eylea
9.6.2.2 Eylea/Zaltrap And The Davis-Smyth Patent Agreements
9.6.3 Regeneron: Sales Forecast 2015-2025
9.6.4 Regeneron: Ophthalmic Drugs Development Pipeline, 2015
9.7 Valeant
9.7.1 Valeant: Ophthalmic Drugs Portfolio, 2015
9.7.2 Valeant: Recent Developments
9.7.2.1 Valeant’s Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
9.7.3 Valeant: Sales Forecast 2015-2025
9.7.4 Valeant: Ophthalmic Drugs Development Pipeline, 2015
9.8 Pfizer
9.8.1 Pfizer: Ophthalmic Drugs Portfolio, 2015
9.8.1.1 Xalatan/Xalacom – Pfizer’s Leading Ophthalmic Products
9.8.1.2 Macugen – Valeant/Pfizer
9.8.2 Pfizer: Recent Developments
9.8.2.1 Pfizer Attempts to Acquire AstraZeneca
9.8.3 Pfizer: Sales Forecast 2015-2025
9.8.4 Pfizer: Ophthalmic Drugs Development Pipeline, 2015
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2015-2025
9.10 Senju
9.10.1 Senju: Ophthalmic Drugs Portfolio
9.10.2 Senju: Sales Forecast 2015-2025
9.10.3 Senju: Ophthalmic Drugs Development Pipeline, 2015
9.10.3.1 Y 39983 (SNJ 1656)
9.10.3.2 Difluprednate (SJE-2079)
10. Ophthalmic Drugs: Research And Development Pipeline, 2015-2025
10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts In Retinal Disorders
10.2 Drugs For Retinal Disorders: Development Pipeline, 2015
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.2.2 Retinal Disorders: Filed or Recently Launched
10.2.2.1 Compaq Sipp (conbercept) – Chengdu Kanghong Pharmaceutical
10.2.2.2 Lipidil (fenofibrate) – Abbott
10.2.2.3 Iluvien (fluocinolone) – Alimera Sciences
10.2.3 Drugs In Phase 3 Development For Retinal Disorders
10.2.3.1 Fovista and Zimura – Ophthotech Corporation
10.2.3.2 Lampalizumab (anti-Factor D Fab) – Roche
10.2.3.3 MC-1101 (hydralazine) – MacuCLEAR
10.2.3.4 Tandospirone (serotonin 1A agonist) – Alcon (Novartis)
10.2.3.5 UF-021 (unoprostone) – R-Tech Ueno
10.2.4 Drugs In Phase 2 Development For Retinal Disorders
10.2.4.1 AKB-9778 (Tie2 activator) – Aerpio Therapeutics
10.2.4.2 Luminate (ALG-1001; Integrin peptide therapy) – Allegro/Senju
10.2.4.3 AGN150998 And MP0260 (Anti-VEGF DARPins) – Allergan
10.2.4.4 AGN208397 (beclomethasone) – Allergan
10.2.4.5 CPC 551 – Colby Pharmaceutical
10.2.4.6 Darapladib And GSK933776 – GlaxoSmithKline
10.2.4.7 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis)
10.2.4.8 iCo-007 (antisense inhibitor of C-raf kinase mRNA) – iCo Therapeutics
10.2.4.9 iSONEP (sonepcizumab) – Lpath
10.2.4.10 LFG316 (anti-C5 mAb) – Novartis
10.2.4.11 Novadur (Intravitreal brimonidine implant) – Allergan
10.2.4.12 Optina (danazol) – Ampio Pharmaceuticals
10.2.4.13 PF-655 (synthetic siRNA) – Quark/Pfizer
10.2.4.14 Premiplex (protein replacement therapy) – Shire
10.2.4.15 Renexus (ciliary neurotrophic factor) – Neurotech
10.2.4.16 Squalamine (anti-angiogenic drug) – OHR Pharmaceutical
10.2.4.17 Zybrestat (fosbretabulin) – Oxigene/Symphony VIDA
10.2.5 Drugs In Phase 1 And Pre-clinical Development For Retinal Disorders
10.2.5.1 BDM-E – BioDiem
10.2.5.2 NADPH Oxidase Inhibitors – Alimera Sciences
10.2.5.3 NS2 (aldehyde trap) – Aldeyra Therapeutics
10.2.5.4 PAN-90806 (topical VEGF inhibitor) – PanOptica
10.2.5.5 Plasma Kallikrein Inhibitors (KVD001) – KalVista
10.2.5.6 QLT091001 (synthetic retinoid) – QLT
10.3 Drugs For Allergic, Inflammatory And Infective Ophthalmic Conditions: Development Pipeline, 2015
10.3.1 Drugs In Phase 3 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.3.1.1 EGP-437 (dexamethasone) – EyeGate Pharmaceuticals
10.3.1.2 IBI-10090 and IBI-20089 – Icon Bioscience
10.3.1.3 LE-MPP (loteprednol etabonate) – Kala
10.3.2 Drugs In Phase 2 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.3.2.1 CF101 (adenosine A3 receptor agonist) – Can-Fite BioPharma and OphthaliX
10.3.2.2 FST-100 (povidone-iodine/dexamethasone) – ForeSight Biotherapeutics
10.3.2.3 NVC-422 (auriclosene) – NovaBay
10.3.2.4 Sarilumab – Regeneron
10.3.2.5 V404 PDS – ForSight VISION
10.3.3 Drugs In Phase 1 And Pre-clinical Development For Allergic, Inflammatory and Infective Ophthalmic Conditions
10.3.3.1 Finafloxacin – MerLion Pharmaceuticals/Novartis
10.4 Drugs For Glaucoma: Development Pipeline, 2015
10.4.1 Drugs In Phase 2&3 Development For Glaucoma
10.4.1.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) – Valeant
10.4.1.2 AMA0076 (ROCK inhibitor) – Amakem
10.4.1.3 Rhopressa (AR-13324; ROCK and NET inhibitor) And Roclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals
10.4.2 Drugs In Phase 1 And Pre-clinical Development For Glaucoma
10.5 Drugs For Dry Eye: Development Pipeline, 2015
10.5.1 Drugs In Phase 3 Development For Dry Eye
10.5.1.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics
10.5.1.2 Lifitegrast (integrin antagonist) – Shire
10.5.1.3 MIM-D3 (tyrosine kinase receptor antagonist) – Valeant
10.5.1.4 SI-614 (modified hyaluronate) – Seikagaku
10.5.2 Drugs In Phase 2 Development For Dry Eye
10.5.2.1 ESBA105 (TNF-alpha antibody) – Alcon (Novartis)
10.5.2.2 Kineret (anakinra: IL-1 receptor antagonist) – Amgen/Sobi
10.6 Other Drugs In The Development Pipeline For Ophthalmic Conditions
10.6.1 Brimonidine For Eye Whitening – Valeant
10.6.2 GS-101 (aganirsen) – Gene Signal
10.6.3 Omidria (phenylephrine/ketorolac) – Omeros
11. Qualitative Analysis Of The Ophthalmic Drugs Market, 2015-2025
11.1 Market Factors Influencing Ophthalmic Drugs
11.2 SWOT Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
11.2.1 Strengths
11.2.1.1 A Healthy R&D Pipeline
11.2.1.2 Advances In Drug Delivery Technologies
11.2.1.3 Support For Reimbursement And Payment Approvals
11.2.1.4 Gene Therapy And RNA Interference Technology
11.2.1.5 New Ophthalmic Therapeutic Applications For Drugs
11.2.1.6 Development Of Neuroprotective Anti-Glaucoma Medications
11.2.1.7 Biomarkers As Tools For Better Diagnosis And Treatment
11.2.2 Weaknesses
11.2.2.1 Patient Adherence To Treatment
11.2.2.2 High Treatment Burden On Patients And Healthcare Providers
11.2.2.3 Under-Diagnosis And Under-Treatment
11.2.3 Opportunities
11.2.3.1 Sustained-Release Ocular Implants
11.2.3.2 The Impact Of A Rapidly Ageing Global Population
11.2.3.3 Increasing Prevalence Of Eye Diseases And Diabetes
11.2.3.4 Glaucoma And Retinal Disorders Will Have the Most-Marked Increases In Prevalence
11.2.3.5 Unmet Clinical Need In Many Disease Areas
11.2.3.6 Economic Growth In Emerging Market Provide Opportunity For Expansion
11.2.4 Threats
11.2.4.1 Intensifying Price Regulation In The Market
11.2.4.2 Generic Competition – Likely Erosion Of Sales For Market Leading Brands
11.2.4.3 Rising Costs Of R&D
11.2.4.4 Biosimilars – A Potent Threat To Ophthalmic Drugs’ Success
11.3 Porter’s Five Force Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
11.3.1 Threat of New Entrants
11.3.2 Rivalry Among Competitors
11.3.3 Power of Suppliers
11.3.4 Threat of Substitutes
11.3.5 Power of Buyers
12. Expert Opinions from Our Primary Research
12.1 Interview with Dr Patrik De Haes, CEO and Mr Wouter Piepers, Global Head Of Corporate Communications & Investor Relations At ThromboGenics nv
12.1.1 The Ophthalmic Drug Segments Presenting Growth Opportunities
12.1.2 Jetrea As A Game-Changer In The Treatment Of Vitreomacular Adhesion
12.1.3 The Need To Embrace Novel Treatments
12.1.4 Future Plans For Jetrea
12.1.5 Expanding Treatment Indications And Strategies For Maximising Product Potential
12.1.6 Will Jetrea Be A Substitute For Surgery In Vitreomacular Adhesion Patients?
12.1.7 Development Efforts For Jetrea In Retinal Vein Occlusion
12.1.8 Future Prospects For The Ophthalmic Drugs Market
12.2 Interview With A Spokesperson From Akorn Pharmaceuticals
12.2.1 New Formulation Strategies For Cosopt, Zioptan And Azasite
12.2.2 Expansion Plans For Akorn’s Ophthalmic Portfolio
12.2.3 Tackling Key Unmet Needs Within Ophthalmics
12.2.4 Akorn’s Future Plans For Growth
13. Conclusions
13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
13.2 Leading Sectors In Ophthalmic Drugs In 2014
13.3 Leading Regions In The Ophthalmic Drugs Market In 2014
13.4 Leading Companies In The Ophthalmic Drugs Market, 2014
13.5 What Does The Future Hold For Ophthalmic Drugs?
【レポート販売概要】
■ タイトル：眼科用薬の世界市場：ドライアイ、緑内障、網膜障害、アレルギー性・炎症性・感染性眼科疾患■ 英文：Ophthalmic Drugs Market Forecast 2015-2025 : Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs
■ 発行日：2015年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN5072208
■ 調査対象地域：グローバル
- IPMフェロモンの世界市場分析：製品別（性フェロモン、凝集フェロモン、産卵抑制フェロモン、アラームフェロモン）、セグメント予測、-2020Global IPM Pheromones Market is expected to reach USD 2.45 billion by 2020, according to a new study by Grand View Research, Inc. Sex pheromones were widely used in mating disruption techniques of IPM for crop protection in order to increase agricultural yield. Mating disruption being the most effective IPM technique is expected to witness wide acceptance globally thus augmenting sex pheromones de …
- 警報監視の世界市場：車両監視、建物監視、環境監視、設備監視Alarm monitoring refers to all forms of technologies that enable communication between an installed alarm system and a central monitoring station through wired or wireless connections. Communication technologies such as wired telecommunication networks and IP networks are expected to dominate the global alarm monitoring market during the forecast period. The market share of IP network is expected …
- 電動機の世界市場：ADモータ、DCモータGlobal electric motor sales market is projected to grow at a CAGR of 6.38% during 2015-2020, to reach a value of USD 125.02 billion by 2020. The growth is attributed to the increase in investments in major industries such as oil & gas, metal & mining, power utilities and automobile production along with the rise in commercial and residential infrastructure growth. Electric motors are widely used i …
- 世界のeラーニング市場動向（2012-2016）TechNavio's analysts forecast the Global e-Learning market to grow at a CAGR of 7.90 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in initiatives to promote e-Learning. The Global e-Learning market has also been witnessing consolidation of the market. However, educational policies inhibiting the growth of the market could pose a challe …
- 自動車アクスル（車軸）及びプロペラシャフトの世界市場：ライブ車軸、固定車軸、タンデム車軸、フロント/リア/車軸間プロペラシャフトThe demand for automotive axles and propeller shafts is governed by global vehicle production. Axles are designed to bear the weight of the vehicle, and are required to be lightweight for fuel-efficiency and structurally stiff to handle the vehicle’s powertrain requirements given the increased torque. Tier I suppliers are developing new technologies, focusing on reduction of fuel consumption. Supp …
- 垂直離着陸（VTOL）無人機（UAV）の世界市場2016-2020About VTOL UAV VTOL UAVs are are capable of performing vertical take-off and landing and do not require a runway. VTOL UAVs can be further classified into multi-rotors (quadcopters, hexacopters, and octocopters), helicopter-configured UAVs, and tiltrotor VTOL UAVs. These UAVs are mostly used for applications where stability and hover capability is crucial. Technavio’s analysts forecast the global …
- バイオ殺虫剤の世界市場：バチルス・チューリンゲンシス、ボーベリア・バシアナ、バーティシリウム・レカニ、メタリジウムThe bioinsecticides market is projected to grow at a CAGR of 18.3% from 2016 to 2021, to reach a projected value of USD 3.18 Billion by 2021. The increased level of pest attacks due to climatic changes and rise in demand for biological pest control know-hows result in the growth of the bioinsecticides market. The market is further driven by factors such as technology and product development of inn …
- 動物診断の世界市場予測（～2023年）：動物診断機器、動物診断消耗品The veterinary diagnostics market is projected to reach USD 4.00 billion by 2023 from USD 2.63 billion in 2018, at a CAGR of 8.8%. Factors such as growing companion animal population, growing prevalence of animal zoonotic diseases, rising demand for animal-derived food products, rising demand for pet insurance & growing animal health expenditure, and the increasing number of veterinary practitione …
- 動物用成長促進剤および機能向上剤の世界市場：抗生物質、ホルモン、飼料用酵素、プロバイオティクス、プレバイオティクス、有機酸、植物、βアゴニストThe animal growth promoters market is expected to reach USD 9.60 Billion in 2020 from USD 7.56 Billion in 2015, growing at a CAGR of 5%. The global animal growth promoters market is segmented on the basis of product and animal. By product, the market is categorized into antibiotics, hormonal growth promoters, beta agonist growth promoters, feed enzymes, probiotics and prebiotics, organic acids, ph …
- 帯状疱疹ワクチンのグローバル市場機会分析（MarketVIEW: Herpes zoster vaccines）Varicella-zoster virus (VZV) is a ubiquitous human alphaherpesvirus, which after infection in childhood causes a relatively mild self-limiting illness. However, if the virus becomes reactivated later on in life it can cause a painful rash (shingles), often leading to postherpetic neuralgia (PHN). PHN has a significant economic burden because patients require systemic anti-viral therapy and pain ma …
- リップスティックの世界市場：製品種類別（マット、グロッシー、リップパウダー、その他）、フォーム別（スティック、液体、パレット）、流通経路別（スーパーマーケット/ハイパーマーケット、専門店、オンラインストア）Lipstick is a makeup product that is used for beautification of lips. The primary ingredient used to make lipstick includes waxes, oil, and pigments. The lipstick market size was valued at $8.2 billion in 2018, and is expected to reach $12.5 billion by 2026, registering a CAGR of 5.5% from 2019 to 2026. They are available in may shades and colors including nude, maroon, red, pink, purple, and othe …
- Optina (Microvascular Complications of Diabetes)：市場予測と分析（～2022）Optina (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely …
- ストリーミング分析ソリューションの世界市場Streaming analytics have become an important tool for businesses to remain competitive among the competitors in the global market. The streaming analytics market has been segmented by various industry verticals and the major applications of streaming analytics platforms within these verticals. Streaming analytics providers play a vital role in assisting various organizations in quickly reacting to …
- 黒色腫の疫学的予測（～2023）EpiCast Report: Melanoma - Epidemiology Forecast to 2023 Summary Melanoma of the skin is a malignant neoplasm of melanocytes and is a significant source of morbidity and mortality worldwide. GlobalData epidemiologists forecast that the diagnosed prevalent cases of melanoma of the skin (all ages) in the 8MM will increase from 155,057 diagnosed prevalent cases in 2013 to 207,606 diagnosed prevalent …
- ベビー用品の世界市場：ベビーフード、ミルク、おむつ、トイレタリー、ウェットティッシュ、ベビーカー、ベビーベッド、カーシートAbout Baby Health and Personal Care Baby health and personal care products include baby foods and infant formulas; baby diapers; baby toiletries; baby wipes; and baby safety and convenience products such as baby strollers and prams, baby cribs, and baby car seats. TechNavio's analysts forecast the Global Baby Health and Personal Care market to grow at a CAGR of 7.29 percent during the period 2014- …
